Pharmacogenomics in Psychiatric Practice

El‐Mallakh, Rif S.; Roberts, R. Jeannie; El-Mallakh, Peggy; Findlay, Lillian Jan; Reynolds, Kristen K.

doi:10.1016/j.cll.2016.05.001

Cited by 11 publications

(3 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combinatorial pharmacogenomic testing encompassing more complete genomic information by combining moderate-risk alleles has become commercially available. 8 …”

Section: Optimizing the Treatment In Psychiatrymentioning

confidence: 99%

Novel treatment options in depression and psychosis

Češková¹,

Šilhán²

2018

NDT

View full text Add to dashboard Cite

In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets. In depression, treatment resistance to antidepressive pharmacotherapy represents one of the most important clinical challenges. Switching to monotherapy with new multimodal/multifunctional antidepressants and augmentation with new atypical antipsychotics (aripiprazole and brexpiprazole) may be promising options. Further, current evidence supports utility and safety of adjunctive treatment of nutraceuticals. Novel approaches being studied include ketamine and opioids. Recent advances in technology and emerging knowledge about dysfunctional brain circuits and neuroplasticity have led to the development of different new neuromodulation techniques usually used as add-on therapy. Antipsychotics are still the cornerstone of the current treatment of schizophrenia. Two new partial dopamine agonists, brexpiprazole and cariprazine, are now available in addition to aripiprazole. Although the mechanisms of action are similar, the two agents differ in terms of their pharmacodynamic profiles. Further, two new formulations of long-acting injections of second-generation antipsychotics (aripiprazole lauroxil and 3-month paliperidone palmitate) were introduced into clinical practice. New treatment options not yet available include cannabidiol, glutamate modulators, and nicotine receptors agonists.

show abstract

“…Combinatorial pharmacogenomic testing encompassing more complete genomic information by combining moderate-risk alleles has become commercially available. 8 …”

Section: Optimizing the Treatment In Psychiatrymentioning

confidence: 99%

Novel treatment options in depression and psychosis

Češková¹,

Šilhán²

2018

NDT

View full text Add to dashboard Cite

show abstract

“…A standard dosage of the drug may show inadequate efficacy in some individuals and serious toxicity in others. To name a few, the drug substrates of CYP2D6 include atomoxetine (a non-stimulant for ADHD), clozapine (an antipsychotic for schizophrenia), and venlafaxine (an antidepressant), among psychiatric medications, as in Table 1 [4,25]. For these drugs, standard doses will result in higher-than-optimal active levels when individuals have absent or deficient CYP2D6 activity.…”

Section: Cyp2d6 and Cyp2c9 Genesmentioning

confidence: 99%

Pharmacogenomic Biomarkers and Their Applications in Psychiatry

Kam

Jeong

2020

Genes

View full text Add to dashboard Cite

Realizing the promise of precision medicine in psychiatry is a laudable and beneficial endeavor, since it should markedly reduce morbidity and mortality and, in effect, alleviate the economic and social burden of psychiatric disorders. This review aims to summarize important issues on pharmacogenomics in psychiatry that have laid the foundation towards personalized pharmacotherapy and, in a broader sense, precision medicine. We present major pharmacogenomic biomarkers and their applications in a variety of psychiatric disorders, such as depression, attention-deficit/hyperactivity disorder (ADHD), narcolepsy, schizophrenia, and bipolar disorder. In addition, we extend the scope into epilepsy, since antiepileptic drugs are widely used to treat psychiatric disorders, although epilepsy is conventionally considered to be a neurological disorder.

show abstract

“…Combinatorial pharmacogenomic testing encompassing more complete genomic information by combining moderate-risk alleles has become commercially available. 8 Patient-centered medicine seeks to focus attention first on the need and concerns of the patient and to consider social and economic factors. 9 Knowledge of the pharmacology of psychiatric medications is necessary but not sufficient for the delivery of appropriate, safe, and effective care.…”

Section: Introduction (Burden Of Mental Disease)mentioning

confidence: 99%

Novel Treatment Options in Depression and Psychosis

Češková

2017

Clinical Therapeutics

View full text Add to dashboard Cite

Abstract:In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets. In depression, treatment resistance to antidepressive pharmacotherapy represents one of the most important clinical challenges. Switching to monotherapy with new multimodal/multifunctional antidepressants and augmentation with new atypical antipsychotics (aripiprazole and brexpiprazole) may be promising options. Further, current evidence supports utility and safety of adjunctive treatment of nutraceuticals. Novel approaches being studied include ketamine and opioids. Recent advances in technology and emerging knowledge about dysfunctional brain circuits and neuroplasticity have led to the development of different new neuromodulation techniques usually used as add-on therapy. Antipsychotics are still the cornerstone of the current treatment of schizophrenia. Two new partial dopamine agonists, brexpiprazole and cariprazine, are now available in addition to aripiprazole. Although the mechanisms of action are similar, the two agents differ in terms of their pharmacodynamic profiles. Further, two new formulations of long-acting injections of second-generation antipsychotics (aripiprazole lauroxil and 3-month paliperidone palmitate) were introduced into clinical practice. New treatment options not yet available include cannabidiol, glutamate modulators, and nicotine receptors agonists.

show abstract

Pharmacogenomics in Psychiatric Practice

Cited by 11 publications

References 96 publications

Novel treatment options in depression and psychosis

Novel treatment options in depression and psychosis

Pharmacogenomic Biomarkers and Their Applications in Psychiatry

Novel Treatment Options in Depression and Psychosis

Contact Info

Product

Resources

About